GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:
Vitrolife (STO:VITR)
· Sales amounted to SEK 187 (162) million, corresponding to an increase of 15 percent in SEK. Sales growth was 16 percent in local currency.
· Operating income before depreciation and amortization (EBITDA) amounted to SEK 62 (54) million, corresponding to a margin of 33 (33) percent. Operating income included one-time expenses of SEK 5 million related to the planned consolidation of the time-lapse business. Adjusted for this, the margin amounted to 36 percent.
